Novartis News Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis
- Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older1
Novartis News Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis
- Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older1
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia